Physicians' Academy for Cardiovascular Education

Biomarker levels differ between HFpEF and HFrEF patients

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction

Literature - Tromp J, Khan MAF, Klip IT, et al. - J Am Heart Assoc. 2017;6:e003989.


The fact that effective treatment options for heart failure with preserved ejection fraction (HFpEF) are lacking, highlights the poor understanding of the pathophysiology of this condition [1-4]. Differences in patient-specific biomarker profiles between HFpEF and heart failure with reduced ejection fraction (HFrEF) may provide insights to the differences in their pathophysiology and help develop effective treatment strategies for HFpEF [5].

In this study, levels of 33 biomarkers, patterns of correlation and the predictive value of these biomarkers were assessed in 460 patients with HFpEF or HFrEF at discharge after hospitalization for acute heart failure. Chosen biomarkers reflected different pathophysiological domains (inflammation, oxidative stress, remodelling, cardiac stretch, angiogenesis, arteriosclerosis, renal function).

Main results


Biomarker levels differ in HFpEF and HFrEF patients, mainly in the domains of cardiac stretch and inflammation. The angiogenesis marker neuropilin and remodeling marker osteopontin were found to only hold predictive value in HFpEF. The difference in biomarker levels may reflect the different pathophysiology of HFpEF and HFrEF.


Show references

Download slide in ppt Find this article online at JAHA

Share this page with your colleagues and friends: